Introduction
The use of highly active antiretroviral therapy (HAART) has modified the course of human immunodeficiency virus (HIV) infection, reducing both morbidity and mortality resulting from its classic opportunistic infections and thus increasing the life expectancy of the affected patients. 1, 2 In this context, it has been found that hepatic dysfunction is an important cause of complications and death among this population, next to metabolic and cardiovascular complications. In addition, hepatic cellular enzyme elevations (ALT [alanine aminotransferase] and AST [aspartate aminotransferase]) and ultrasonographic liver alterations are very frequently found in these patients. 3 The use of antiretroviral (ARV) medications has been linked to the emergence of severe adverse effects, including mitochondrial toxicity. The liver also appears to be among the affected organs. Nevertheless, different studies suggest that these patients' mitochondrial alterations could be associated to other etiological factors. The goal of this study was to analyze hepatic mitochondria ultrastructural changes in HIV-infected patients under investigation for hepatopathy. Semiquantitative analysis of mitochondria was performed in liver biopsies from 10 patients divided into 2 groups: Group 1 consisted of 5 patients who had never used ARV medications; group 2 consisted of 5 patients who reported previous use of either zidovudine or didanosine. Significant mitochondrial alterations were found in both groups. The summation of the mitochondrial alterations was higher in group 1 (P < .05) when compared with those who had previously used ARV medications. Therefore, the authors conclude that severe mitochondrial alterations occur in HIV-infected patients who have never been submitted to antiretroviral therapy. Keywords: liver; HIV; mitochondria; ultrastructural changes; antiretroviral drugs toxicity diagnosis is usually clinical. Different laboratory tests may be useful, especially serum lactate levels and, occasionally, mitochondrial DNA (mtDNA) serum levels in mononuclear blood cells. [5] [6] [7] The use of ultrastructural analysis with this aim is not habitual and is generally reserved for specific cases. Studies regarding ultrastructural alterations in liver or other tissues from HIV-infected patients are rare. The most frequently found alterations are: giant mitochondria, mitochondrial hyperplasia and polymorphism, and loss of mitochondrial crista. [8] [9] [10] [11] [12] [13] Clinical data in reference to the patients involved in such infrequent studies are weak and insufficient. These studies usually do not clarify whether the individuals affected by hepatic mitochondrial ultrastructural changes were or were not undergoing ART. Duarte et al, 14 when conducting liver biopsies of HIV-infected patients using the electron microscope, observed modifications in the Disse space (Ito cell hyperplasia with lipid vacuole increase, and lymphocyte and macrophage activation signs) and sinusoidal dilatation associated with hypertrophy. She also observed various degenerative aspects in the mitochondria. To date, at least as far as the authors' knowledge goes, no study has yet observed hepatic mitochondria ultrastructural changes in patients who did not have other active liver diseases and had not undergone ART. Data found in the literature do not allow us to arrive at a conclusion regarding whether HIV-infected patients who never used ARV medications in the past or present could actually show the above-mentioned mitochondrial alterations that were once associated with the use of ARV drugs. It was with the goal of analyzing such questions that this study was conceived.
Objectives
We wanted to study the ultrastructural alterations in hepatocyte mitochondria from HIV-infected patients, comparing those who did not undergo ART with those who did.
Patients and Methods

Study Population
We analyzed retrospectively the medical files of patients admitted to the Infectious and Parasitic Diseases Division (Hospital das Clínicas, University of Sao Paulo Medical School) from 1988 to 1994, focusing on the histopathological findings of liver biopsies and specimens submitted for electron microscopy.
Every patient had the confirmed diagnosis of HIV infection. The diagnosis was established through serologic tests and the detection of specific antibodies against the virus. Identification of HIV antigen p24 was also used for confirmatory diagnosis. The patients all had liver dysfunction under investigation, and liver biopsy was indicated when laboratory testing did not suffice to clarify the established hepatic alterations. The most frequent signs and symptoms that prompted clinical investigation were jaundice, liver enzyme elevations, hepatosplenomegaly, and weight loss. As may be seen in Table 1 , at the time of biopsy, most patients had less than 200 cells/mm 3 cells, and ALT levels were elevated. Samples and information from 20 patients from this period of time were identified, and 10 patients were selected. The remaining 10 cases were excluded because of insufficient clinical data.
Concerning hepatitis virus B and C (HBV and HCV) coinfection, it must be noted that 2 individuals from each group of patients had positive serologic markers for these infections. Patients were thus divided into 2 groups, according to ARV exposure history: 5 of the patients had never received ARV drugs (group 1), and 5 had used NRTIs (zidovudine or didanosine; group 2).
Liver Biopsy
The histopathological alterations observed in the liver biopsies were reviewed so that viral inclusions were searched and, through specific coloration methods (Brown-Breen, Ziehl-Neelsen, and Grocott), bacteria, mycobacteria, and fungi were excluded.
Electron Microscopy and Semiquantitative Scoring of Ultrastructural Mitochondrial Alterations
The samples that were chosen for electron microscopy were prepared through the fast processing method 15 and analyzed using the JEOL 1010 electron microscope. Mitochondrial alterations were analyzed in at least 10 micrographs of hepatocyte cytoplasm in each liver by 2 independent and trained observers. The scores were defined as 0 when all mitochondria showed normal structure, 1 when most mitochondria showed normal structure, 2 when most mitochondria showed deranged structure, and 3 when all mitochondria showed deranged structure. The following characteristics were studied: size modifications (hypertrophy, giant mitochondria); shape alterations; membrane rupture or irregularity; matrix and crista damage; electrodense granule density; and the presence of crystalline inclusions, calcification, picnosis, balonization, and cytolysis. The mean value of individual aspects and also the summation of the values obtained were used for comparison between liver samples from patients in both groups. Quantitative data were compared between patients' groups using 2-sample Student's t tests, after variance check, and considered significant when P < .05.
Results
The histology reappraisal from blocks showed inespecific minor hepatic changes, or mild hepatic steatosis in a few cases ( Table 1 ). The histopathological alterations review of the liver biopsies, which consisted of the search for viral inclusions and the use of specific colorations (Brown-Breen, Ziehl-Neelsen, and Grocott), was unable to determine different etiological agents for the clinical alterations under investigation.
The ultrastructural study revealed important hepatocyte mitochondrial change, with no predilection to specific acinar zones (Figure 1) . The intensity of alterations had a varying distribution, not only in each individual hepatocyte but also in groups of adjacent hepatic cells. The degree of damage did not differ in the 2 patient groups under analysis. Qualitative analyses showed areas of mitochondrial hyperplasia, with changes in shape (elongation, balonization, bizarre shapes) and size (megamitochondria) in both groups. We also noticed an increased number of dense granules, matrix condensation, crista loss, lamellar distributed filamentous material, and crystaloid material. Semiquantitative data are documented in Figure 2 . Mitochondrial alterations were present in both groups, with no significant differences between them. However, the intensity of dense granules was higher in the previously untreated patient group's mitochondria (P < .05), as can be seen in Figure 3 . We also noticed that the mean of the selected mitochondrial alterations was higher in the same group of patients when compared with those who had previously used ARV medications (P < .05), despite the small number of individuals under analyses. This can be seen in Figure 4 .
Discussion
The mechanism involved in the development of hepatic alterations in patients on NRTIs has not been completely explained. Even so, it is believed that mitochondrial toxicity triggered by these drugs is the most probable reason for liver damage. NRTIs disrupt the function of the reverse transcriptase enzyme, leading to a premature interruption of the virus's DNA synthesis. Besides its action against Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; ARV, antiretroviral; NT, not tested; NA, not applicable. a Above superior normal limit. HIV synthesis, NRTIs can inhibit γ-polymerase, an enzyme involved in the replication process of mtDNA. When about 70% of the mtDNA has already been damaged, cells might start to suffer because of consequent anaerobic conditions and lactic acid production. The mtDNA depletion affects the aerobic lipid and carbohydrate metabolism, resulting in a buildup of pyruvate/lactate and fatty acids, which may, respectively, result in acidosis and lipoatrophy. 5, 6, 16, 17 It must be remembered that HIV [16] [17] [18] and HCV 19,20 themselves have been identified as causes of hepatic mitochondrial alterations. Various authors have observed that HIV patients who never underwent ART had a decrease in mtDNA when compared with noninfected individuals. This led some authors to infer that HIV itself, 18 either directly or through cytokine induction, causes mitochondrial alterations, hence increasing the risk of mitochondrial toxicity at ART introduction. [16] [17] [18] HCV, on the other hand, has been associated with lipoperoxidation, which might lead to mitochondrial dysfunction and mtDNA depletion. 19, 20 This study's results have shown that HIV-infected patients with no history of ARV medication use may have various important ultrastructural alterations in hepatocyte mitochondria. It was also established that such mitochondrial alterations also occur among HIV-infected patients who had been treated with ARV medications.
Our data also indicate that in the group of patients who had not undergone ART the sum of mitochondrial alterations was higher (P < .05) than in the group in which patients were using ARV medications. Such results might suggest that mitochondria of patients previously treated with NRTIs are generally in better condition. On the other hand, it is plausible that the apparent protective effect of ARV medications over mitochondrial alterations is just the result of the small number of patients under analysis. Moreover, another possibility is that the use of these drugs might have had some sort of immunomodulatory effect for these patients, improving their health conditions. In this way, the negative effects of HIV and other factors that were harmful to the mitochondria could be neutralized, even if only mildly. Possibly, some portion of the mitochondrial alterations observed among untreated patients were a consequence of the HBV and HCV coinfections that are sometimes present. Two patients, one in each group, had positive serologic reactions for AgHBs and anti-HCV. Six patients were not tested for HCV, because this serologic reaction was not available at the time of investigation. Mitochondrial alterations in HIV/HCV infected patients have been described, 13 and therefore, their finding might be, at some level, justified by the coinfection.
It must be noted that these patients did not present with histological characteristics representative of active hepatitis infection. Mitochondrial changes of size and paracrystalline inclusions have also been associated with numerous clinical situations such as alcohol abuse, chloramphenicol use, obstructive jaundice, and other less frequent medical conditions. [21] [22] [23] Other authors have observed modifications in the hepatic mitochondria of cocaine addicts and related such findings to the use of this drug. 24 The patients included in this study were HIVinfected individuals with advanced disease, frequently with a background of both inhalatory and intravenous drug abuse. They had established liver dysfunction under investigation and were on medications such as antifungal drugs and sulfas. It is reasonable to think consequently that the hepatocyte alterations resulted from multiple factors in combination rather than from ARV medications exclusively.
Therefore, taking all the above-mentioned issues into consideration, we conclude that the observed mitochondrial alterations are not exclusively a result of the previous use of ARV medications. To the best of the authors' knowledge, this is the only study to date to demonstrate ultrastructural alterations of hepatic mitochondria in patients not previously treated with ARV medications and with no other active hepatic disease. It is our intention through this study to alert physicians to the possibility that there could be various causes for mitochondrial damage in HIV-infected patients, irrespective of whether they are treated with ARV medications. In the group of patients who had undergone ART, it is possible that the hepatic damage caused by NRTIs was somehow modulated by the presence or absence of other causes of mitochondrial aggression. Mitochondrial disease may thus be consequent to the association of many different factors and not exclusively a result of ART, as has been reported by other studies.
